We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-0.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.63B
AUM Growth
+$871M
Cap. Flow
-$403M
Cap. Flow %
-7.15%
Top 10 Hldgs %
32.98%
Holding
166
New
29
Increased
30
Reduced
12
Closed
23

Top Buys

Rank Stock Value
1
OMIC
Singular Genomics Systems, Inc. Common Stock
OMIC
+$235M
2
AHCO icon
AdaptHealth
AHCO
+$145M
3
CMAX
CareMax, Inc. Class A Common Stock
CMAX
+$132M
4
ORGO icon
Organogenesis Holdings
ORGO
+$78.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$50.1M

Top Sells

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$110M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$88.6M
3
BIIB icon
Biogen
BIIB
+$86.7M
4
CNC icon
Centene
CNC
+$67.9M
5
TOI icon
The Oncology Institute
TOI
+$55M

Sector Composition

Rank Sector Weight
1 Healthcare 68.23%
2 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CERT icon
126
Certara
CERT
$1.08B
– –
-600,000
Closed -$16.4M
ELVN icon
127
Enliven Therapeutics
ELVN
$3.69B
– –
-19,866
Closed -$671K
FDMT icon
128
4D Molecular Therapeutics
FDMT
$580M
– –
-150,000
Closed -$6.51M
GBIO
129
DELISTED
Generation Bio
GBIO
– –
-89,778
Closed -$25.6M
INNV icon
130
InnovAge Holding
INNV
$1.5B
– –
-300,000
Closed -$7.74M
PACB icon
131
Pacific Biosciences
PACB
$422M
– –
-468,000
Closed -$15.6M
SHC icon
132
Sotera Health
SHC
$4.97B
– –
-1,111,000
Closed -$27.7M
FTH
133
Faeth Therapeutics
FTH
$727M
– –
-18,750
Closed -$5.45M
STIM icon
134
Neuronetics
STIM
$141M
– –
-919,000
Closed -$11.4M
SYK icon
135
Stryker
SYK
$122B
– –
-59,000
Closed -$14.4M
WOOF icon
136
Petco
WOOF
$774M
– –
-500,000
Closed -$11.1M
GRCL
137
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-400,000
Closed -$6.16M
LABP
138
DELISTED
Landos Biopharma, Inc. Common Stock
LABP
– –
-45,000
Closed -$4.33M
SGFY
139
DELISTED
Signify Health, Inc.
SGFY
– –
-400,000
Closed -$11.7M
RUBY
140
DELISTED
Rubius Therapeutics, Inc
RUBY
– –
-550,000
Closed -$14.6M
OCDX
141
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
– –
-2,352,941
Closed -$45.4M
HRC
142
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
– –
-279,870
Closed -$30.9M
ALXN
143
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-579,248
Closed -$88.6M
CAPAU
144
DELISTED
HighCape Capital Acquisition Corp. Unit
CAPAU
– –
-1,000,000
Closed -$12.9M
2 3 4 5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Deerfield Management's Q2 2021 Portfolio in Review

As of Q2 2021, Deerfield Management held 166 positions worth $5.63B, up 18% from $4.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Deerfield Management withdrew a net $403M in Q2 2021, closing 23 positions and reducing 12 holdings. Its most notable exit was Boston Scientific, an estimated $110M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 71% a quarter earlier, followed by Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Singular Genomics Systems, Inc. Common Stock worth $250M.

  • Deerfield Management's largest Q2 2021 buy was Singular Genomics Systems, Inc. Common Stock: 303,734 shares worth $250M.
  • Deerfield Management added most to AdaptHealth in Q2 2021, an estimated $145M increase.
  • Deerfield Management's biggest Q2 2021 reduction was Centene, cutting an estimated $67.9M.
  • Deerfield Management fully exited Boston Scientific in Q2 2021, selling an estimated $110M.
  • Deerfield Management's ten largest holdings make up 33% of its $5.63B portfolio in Q2 2021.
  • Deerfield Management opened 29 new positions and closed 23 in Q2 2021.
  • Deerfield Management's portfolio value rose 18% quarter-over-quarter to $5.63B.

Based on Deerfield Management's 13F filing for Q2 2021, filed 16 Aug 2021.